Six new treatments aim to improve patient outcomes across key areas
News
Sheffield leads UK trial into stem cell treatment for severe scleroderma
UPSIDE study explores early transplant therapy for rare autoimmune disease
AC Immune’s Tau-targeting therapy shows promise in early Alzheimer’s trial
Early-stage study reveals strong immune response and safety profile for ACI-35.030
Xeltis prepares for commercial launch after strong aXess trial results
EU phase 3 data shows major gains in dialysis access performance
North Star shows promise in phase 2 thyroid trial
Acella and Neuvosyn report positive results for investigational DTE therapy
Greater Manchester launches first vaccine studies through new research centre
GM CRDC begins trials to assess real-world effectiveness of respiratory vaccines
Tezspire recommended for EU approval in nasal polyps
CHMP backs AstraZeneca and Amgen’s therapy for chronic rhinosinusitis
Guselkumab receives CHMP backing for subcutaneous induction in ulcerative colitis
EMA opinion supports expanded use of TREMFYA in phase 3 UC treatment
First patient treated in pivotal trial of Parkinson’s cell therapy
BlueRock begins phase 3 study of bemdaneprocel in Parkinson’s disease
European Commission approves ROMVIMZA for TGCT treatment
Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU
Modus data on sevuparin for CKD to be presented at global GAG symposium
Preclinical results highlight potential of glycosaminoglycan-based therapy
Bimekizumab shows sustained three-year efficacy in hidradenitis suppurativa
Data from trials highlight long-term disease control and quality of life improvements
Nxera and Cancer Research UK begin phase 2a trial of HTL0039732
First patient dosed in study of novel EP4 antagonist for advanced solid tumours
Imfinzi approved for NHS use in limited-stage small cell lung cancer
Durvalumab becomes first immunotherapy recommended for LS-SCLC patients in England and Wales
Vorasidenib approved in UK for treating IDH-mutant brain tumours
MHRA greenlights oral therapy for patients aged 12 and over with grade 2 astrocytoma
